glp-1 pearls Pharmacy Pearls: RAs for Weight Loss There are a lot of

Descriptive analysis Patient demographics (age, sex, and reporter type) and clinical aspects (latency, outcome, and indication) were documented in reports of SSIBs with semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, and albiglutide

Licensed Clinician Oversight Prescribed and monitored by medical professionals FDA-Regulated Manufacturing Compounded in regulated U.S

It is an argument that effectiveness is the product of pharmacology AND real-world adherence

Recently, the STEP-HFpEF trial enrolled 529 non-diabetic patients with HFpEF and obesity, who were randomly assigned to receive either once-weekly semaglutide (2.4 mg) or placebo for 52 weeks

Certain GLP-1 medications are only FDA approved to treat conditions other than weight but may be prescribed to help aid in weight loss

Available from: Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J